Document is current
Any future updates will be listed below
-
Authors
Li, Yan-Ruide https://orcid.org/0000-0002-9858-300X
Nan, Haochen
Liu, Zeyang
Fang, Ying
Zhu, Yichen
Lyu, Zibai
Shao, Zhengyao https://orcid.org/0000-0003-2965-8335
Zhu, Enbo https://orcid.org/0000-0001-8600-8553
Zhang, Bo https://orcid.org/0000-0001-5902-0290
Yang, Youcheng
Shen, Xinyuan https://orcid.org/0009-0002-2788-3993
Chen, Yuning https://orcid.org/0009-0000-8010-670X
Hsiai, Tzung https://orcid.org/0000-0003-1734-0792
Yang, Lili https://orcid.org/0000-0001-6568-0404
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01GM143485)
California Institute for Regenerative Medicine (DISC2-14169)
California Institute for Regenerative Medicine (DISC2-11157)
California Institute for Regenerative Medicine (TRAN1-12250)
- License Information
-
More Information
Article History
Received: 12 March 2025
Accepted: 7 February 2026
First Online: 17 March 2026
Competing interests
: L.Y. is a scientific advisor to AlzChem and Amberstone Biosciences, and a co-founder, stockholder and advisory board member of Appia Bio. None of the declared companies contributed to or directed any of the research reported in this Article. Y.-R.L., H.N., Z. Liu, L.Y. and S.L. filed a patent application related to this work through UCLA Technology Development Group (UCLA TDG), identified as UCLA CASE NO. 2025-209-1, titled ‘Recruitment and activation of car-redirected invariant natural killer T cells’. The remaining authors declare no competing interests.
